Trial Profile
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 31 Jan 2017 Status changed to discontinued as funds are not available.
- 29 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 03 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.